Feasibility of combination allogeneic stem cell therapy for spinal cord injury: a case report.
Cellular therapy for spinal cord injury (SCI) is overviewed focusing on bone marrow mononuclear cells, olfactory ensheathing cells, and mesenchymal stem cells. A case is made for the possibility of combining cell types, as well as for allogeneic use. We report the case of 29 year old male who suffered a crush fracture of the L1 vertebral body, lacking lower sensorimotor function, being a score A on the ASIA scale. Stem cell therapy comprised of intrathecal administration of allogeneic umbilical cord blood ex-vivo expanded CD34 and umbilical cord matrix MSC was performed 5 months, 8 months, and 14 months after injury. Cell administration was well tolerated with no adverse effects observed. Neuropathic pain subsided from intermittent 10/10 to once a week 3/10 VAS. Recovery of muscle, bowel and sexual function was noted, along with a decrease in ASIA score to "D". This case supports further investigation into allogeneic-based stem cell therapies for SCI.
Medistem Inc, San Diego, USA. nhriordan@gmail.com.
Thomas E
TE
Ichim
Fabio
F
Solano
Fabian
F
Lara
Eugenia
E
Paris
Federico
F
Ugalde
Jorge Paz
JP
Rodriguez
Boris
B
Minev
Vladimir
V
Bogin
Famela
F
Ramos
Erik J
EJ
Woods
Michael P
MP
Murphy
Amit N
AN
Patel
Robert J
RJ
Harman
Neil H
NH
Riordan